Semaglutide Can Cut Prevalence of Obesity, CVD in Eligible U.S. Adults
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 22, 2023 -- Semaglutide treatment among eligible U.S. adults can reduce the prevalence of obesity and cardiovascular disease (CVD) events, according to a study published online Aug. 14 in Cardiovascular Drugs and Therapy.
Nathan D. Wong, Ph.D., M.P.H., from the University of California in Irvine, and colleagues applied STEP 1 trial eligibility criteria to adults in the U.S. National Health and Nutrition Examination Survey 2015 to 2018 to estimate eligibility for semaglutide 2.4 mg and the potential impact on obesity and CVD events.
The researchers identified 3,999 U.S. adults weighted to an estimated population size of 93.0 million (38 percent of U.S. adults) who meet the eligibility criteria for STEP 1. Applying STEP 1 treatment effects on weight loss would result in weight reductions of ≥10 percent and ≥15 percent in an estimated 69.1 and 50.5 percent, respectively, translating to a reduction in prevalence of obesity of 46.1 percent. For those without CVD, the estimated 10-year CVD risks were 10.15 and 8.34 percent before and after semaglutide treatment, respectively, resulting in a 1.81 percent absolute risk reduction and 17.8 percent relative risk reduction, corresponding to 1.50 million preventable CVD events over 10 years.
"We now have a weight control therapy that also significantly reduces cardiovascular events beyond the diabetes population where it was originally studied," Wong said in a statement. "It should be considered for patients who are obese or overweight with other risk factors where cardiovascular disease is their leading cause of disability and death."
One author disclosed ties to pharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and partially funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
342 Cardiology Clinics Acquired by Private Equity Firms in 2013 to 2023
WEDNESDAY, July 3, 2024 -- From 2013 to 2023, 342 cardiology clinics were acquired by private equity firms, with 94.7 percent of the acquisitions occurring between 2021 and 2023...
Small Differences in Weight Change With First-Line Antidepressants
MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study...
Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep Apnea
FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.